Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination

Hamidreza Zaheri, Arda Kiani, Siamak Afaghi, Fatemehsadat Rahimi, Mohammadhossein Banitorfi, Amirmohammad Kazemzadeh Norozi, Samaneh Hashemi, Atefeh Abedini


The global COVID-19 vaccination had an undeniable influence on the pandemic management, despite of having reported rare but life-threatening side-effects of vaccines. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare autoimmune complication determined by thrombocytopenia and thrombosis propensity in the circulatory system. The activation of antibodies against platelet factor-4 (PF-4) which mimics the heparin-induced thrombocytopenia (HIT) characteristic is the main known pathogenicity of the disease. Herein, we reported a case of VITT in a middle-aged woman with no previous history of thrombophilia or other medical conditions who presented with thrombosis of the left superficial femoral artery 3-days after receiving the second dose of inactivated BBIBP-CorV (Sinopharm) vaccine. The patient underwent bypass vascular surgery and received none-heparin anticoagulation consistent with high-dose intravenous immunoglobin. Eight days after the discharge, she was subsequently referred to our center with the presentation of sub-massive pulmonary thromboembolism in spite of receiving the prophylactic anticoagulants during follow-up period. Details on side-effects of COVID-19 vaccines, specifically the inactivated ones are yet to be fully ascertained. Clinicians should consider the history of COVID-19 vaccines in thromboembolism patients who do not have well-acknowledged risk factors. Further studies about the necessity of prophylactic anticoagulants and clinical judgment for receiving other vaccines in such patients are required.


VITT; Thrombosis; pulmonary thromboembolism; Sinopharm; vaccine; COVID-19

Full Text:



Quazi S. Vaccine in response to COVID-19: Recent developments, challenges, and a way out. BBRJ. 2021; 5(2):105-109. doi 10.4103/bbrj.bbrj_166_20.

Franchini M, Liumbruno GM, Pezzo M. COVID‐19 Vaccine‐associated Immune Thrombosis and Thrombocytopenia (VITT): diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol. 2021; 107(2): 173-180. doi: 10.1111/ejh.13665.

Aleem A, Nadeem AJ. Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 34033367.

Rahimi FS, Afaghi S, Esmaeili Tarki F, Goudarzi K, Malekpour Alamdari N. Viral Outbreaks of SARS-CoV1, SARS-CoV2, MERS-CoV, Influenza H1N1, and Ebola in 21st Century; A Comparative Review of the Pathogenesis and Clinical Characteristics. Sch Med Stud J. 2020;2(3):1-8.

Basiri, N, M. Koushki, Study of Vaccine Production Abroad and Scientific and Research Challenges of COVID-19 Vaccine Production in Iran. Annals of RSCB. 2021;25(4):17249-56.

Khankeh HR, Farrokhi M, Khanjani MS, et al. The Barriers, Challenges, and Strategies of COVID-19 (SARS-CoV-2) Vaccine Acceptance: A Concurrent Mixed-Method Study in Tehran City, Iran. Vaccines (Basel). 2021; 9(11):1248. doi: 10.3390/vaccines9111248.

Sofonea MT, Roquebert B, Foulongne V, et al. Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021-February 2022. Emerg Infect Dis. 2022; 28(7):1355-1365. doi: 10.3201/eid2807.220033.

Karimi A, Hashemian SMR. Cytokine storm in COVID-19 and the treatment simulacrum. BBRJ. 2020; 4(5):41-48. doi: 10.4103/bbrj.bbrj_128_20.

Garg K, Talwar D, Mahajan SN et al. A review on COVID-19 vaccinations. BBRJ. 2022; 6(1): 50-53. doi: 10.4103/bbrj.bbrj_128_20.

McDonnell T, hornber M, Cooksley T, Jain S, McGlynn S. Left inferior ophthalmic vein thrombosis due to VITT: a case report. QJM. 2022; 114(11):810-811. doi: 10.1093/qjmed/hcab124.

Devi K, Ali N, Nasir N, Mahmood SF. VITT with inactivated SARS-CoV-2 vaccine–index case. Hum Vaccin Immunother. 2022; 18(1):2036556. doi: 10.1080/21645515.2022.2036556.

Hosseinzadeh R, Barary M, Mehdinezhad H, Sio TT, Langer F, Khosravi S. Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination. Res Pract Thromb Haemost. 2022; 6(4):e12750. doi: 10.1002/rth2.12750.

Mahla E, Tantry US, Schoerghuber M, Gurbel PA. Platelet function testing in patients on antiplatelet therapy before cardiac surgery. Anesthesiology. 2020; 133(6):1263-1276. doi: 10.1097/ALN.0000000000003541.

Bérezné A, Bougon D, Blanc-Jouvan F, et al. Deterioration of vaccine‐induced immune thrombotic thrombocytopenia treated by heparin and platelet transfusion: Insight from functional cytometry and serotonin release assay. Res Pract Thromb Haemost. 2021; 5(6):e12572. doi: 10.1002/rth2.12572.

Lentz SR. Cooling down VITT with IVIG. Blood. 2021; 138(11):921-922. doi: 10.1182/blood.2021012819.

DOI: http://dx.doi.org/10.22551/2022.37.0904.10222

Copyright (c) 2022 Hamidreza Zaheri, Arda Kiani, Siamak Afaghi, Fatemehsadat Rahimi, Mohammadhossein Banitorfi, Amirmohammad Kazemzadeh Norozi, Samaneh Hashemi, Atefeh Abedini

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


ISSN: 2360-6975